

THE CLAIMS:

This listing will replace all prior versions and listings of claims in the application.

LISTING OF CLAIMS:

1-17. (Canceled)

18. (Previously Presented) The method of claim 32, wherein said fluorescently-labeled steroid hormone receptor ligand includes a fluorescent label selected from the group consisting of fluorescein, fluoresceinamine, DTAF, Texas Red, BODIPY dyes, Alexa dyes, tetramethylrhodamine (TMR), and conjugatable derivatives thereof.

19. (Previously Presented) The method of claim 32, wherein said ligand binding domain (LBD) of a steroid hormone receptor is fused to an N-terminal domain selected from the group consisting of glutathione-S-transferase (GST), maltose binding protein (MBP), and thioredoxin (TRX).

20-21. (Canceled)

22. (Previously Presented) The method of claim 32, wherein said fluorescently-labeled steroid hormone receptor ligand binds to said LBD with a K_d of less than 20nM.

23. (Canceled)

24. (Previously Presented) The method of claim 32, wherein said fluorescently-labeled steroid hormone receptor ligand is capable of competing with a known ligand of said steroid hormone receptor for binding to said steroid hormone receptor.

25-29. (Canceled)

30. (Previously Presented) The method of claim 22, wherein said K_d is 0.8 ± 0.1 nM and wherein said steroid hormone receptor is GR.

31. (Previously Presented) The method of claim 22, wherein said K_d is 2.5 nM and wherein said steroid hormone receptor is PR.

32. (Currently amended) A method for monitoring a binding interaction of a steroid hormone receptor (SHR) with a test ligand comprising:

(a) a first mixture comprising a fluorescently-labeled steroid hormone receptor ligand, a test compound and a ligand binding domain (LBD) of a steroid hormone receptor selected from the group consisting of an androgen receptor (AR), a glucocorticoid receptor (GR), and a progesterone receptor (PR), and

(b) measuring the fluorescence polarization of the first mixture,

wherein the steroid hormone receptor ligand includes a steroid selected from the group consisting of a 5 α -androstan derivatized at one or more of the 1, 3, 6, 7, 11, 15, 17, 18, or 19 positions with a linker conjugated to a fluorescent label; a 4-androsten derivatized at one or more of the 1, 3, 6, 7, 11, 15, 17, 18, or 19 positions with a linker conjugated to a fluorescent label; 4-pregnen derivatized at one or more of the 3, 6, 7, 11, 17, 19, 20 or 21 positions with a linker conjugated to a fluorescent label; and a dexamethasone derivatized at position 21 with a linker conjugated to a fluorescent label.

33. (Previously Presented) The method of claim 32, further comprising:

- (c) a second mixture comprising a fluorescently-labeled steroid hormone receptor ligand and said ligand binding domain (LBD) of a steroid hormone receptor, and
- (d) measuring the fluorescence polarization of the second mixture.

34. (Previously Presented) The method of claim 33, further comprising:

- (e) comparing the fluorescence polarization of said second mixture and the fluorescence polarization of said first mixture to determine if the test compound affects binding of said fluorescently-labeled steroid hormone receptor ligand to the LBD of a steroid hormone receptor.

35. (Currently amended) The method of claim 32-33, wherein the LBD is a full length steroid hormone receptor.